DLC1 and metastatic neoplasm: Low DLC1 expression also predicts poor therapeutic efficiency of fluoropyrimidine/oxaliplatin in adjuvant chemotherapy and was associated with advanced, metastatic disease and shortened time to recurrence and overall survival.